Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES)

Official Title: Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years (RAMSES)

The purpose of this study is to get more information about the effectiveness and safety of AR101 as an oral immunotherapy for peanut-allergic children and adults. AR101 is a pharmaceutical-grade peanut allergen formulation. And this study seeks to understand if AR101 works better than placebo (an inactive substance that looks identical to the drug being tested and has no peanut allergen in it) for patients with peanut allergies. Studies in peanut-allergic children, adolescents, and young adults have shown that AR101 has promise in treating peanut allergies.
NCT03126227
Robison, Rachel G., MD
Interventional
Yes

Contact Information:

Rachel Robison, MD

Principal investigator

888-573-1833